Covered recipient · General Payments record
CHUN NGAI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$389.89
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $245.07 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $78.70 | 3 |
| Lilly USA, LLC | $31.41 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.07 | 1 |
| Acerta Pharma LLC | $24.24 | 1 |
| Amgen Inc. | $24.20 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $22.01 | 1 |
| GlaxoSmithKline, LLC. | $20.19 | 1 |
| Novo Nordisk AS | $18.25 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.89 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105115826 | CMS |
| ABBVIE INC. | $34.58 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105115828 | CMS |
| ABBVIE INC. | $25.23 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105115830 | CMS |
| Amgen Inc. | $24.20 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117640321 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.24 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123305346 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.07 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117851957 | CMS |
| GlaxoSmithKline, LLC. | $20.19 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116458445 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $22.01 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153751136 | CMS |
| Lilly USA, LLC | $31.41 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135614595 | CMS |
| Novo Nordisk Inc | $18.25 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108569352 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.